Combined Immune Checkpoint Blockade

被引:12
作者
Drake, Charles G. [1 ,2 ,3 ,4 ]
机构
[1] James Buchanan Brady Urol Inst, Dept Oncol, Baltimore, MD USA
[2] James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
关键词
ACTIVATED T-CELLS; CANCER-IMMUNOTHERAPY; EFFECTOR FUNCTION; OVARIAN-CANCER; REGULATORY T; LAG-3; PD-1; IPILIMUMAB; AUTOIMMUNE; TIM-3;
D O I
10.1053/j.seminoncol.2015.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the majority of cancer patients. Immune checkpoint blockade can be combined with several other interventions, including radiation therapy, chemotherapy and cancer vaccines. However, the observation that T cells that are rendered not-responsive or "exhausted" by recognition of tumor antigens express multiple non-overlapping checkpoint molecules suggests that immunotherapy approaches in which multiple checkpoint molecules are blocked may be particularly active in the clinic. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 35 条
[1]
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. [J].
Antonia, Scott Joseph ;
Gettinger, Scott N. ;
Chow, Laura Quan Man ;
Juergens, Rosalyn A. ;
Borghaei, Hossein ;
Shen, Yun ;
Harbison, Christopher ;
Chen, Allen C. ;
Ready, Neal ;
Rizvi, Naiyer A. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2]
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization [J].
Baitsch, Lukas ;
Legat, Amandine ;
Barba, Leticia ;
Marraco, Silvia A. Fuertes ;
Rivals, Jean-Paul ;
Baumgaertner, Petra ;
Christiansen-Jucht, Celine ;
Bouzourene, Hanifa ;
Rimoldi, Donata ;
Pircher, Hanspeter ;
Rufer, Nathalie ;
Matter, Maurice ;
Michielin, Olivier ;
Speiser, Daniel E. .
PLOS ONE, 2012, 7 (02)
[3]
CHARACTERIZATION OF THE LYMPHOCYTE-ACTIVATION GENE 3-ENCODED PROTEIN - A NEW LIGAND FOR HUMAN-LEUKOCYTE ANTIGEN CLASS-II ANTIGENS [J].
BAIXERAS, E ;
HUARD, B ;
MIOSSEC, C ;
JITSUKAWA, S ;
MARTIN, M ;
HERCEND, T ;
AUFFRAY, C ;
TRIEBEL, F ;
PIATIERTONNEAU, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :327-337
[4]
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 [J].
Bettini, Maria ;
Szymczak-Workman, Andrea L. ;
Forbes, Karen ;
Castellaw, Ashley H. ;
Selby, Mark ;
Pan, Xiaoyu ;
Drake, Charles G. ;
Korman, Alan J. ;
Vignali, Dario A. A. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (07) :3493-3498
[5]
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].
Blackburn, Shawn D. ;
Shin, Haina ;
Haining, W. Nicholas ;
Zou, Tao ;
Workman, Creg J. ;
Polley, Antonio ;
Betts, Michael R. ;
Freeman, Gordon J. ;
Vignali, Dario A. A. ;
Wherry, E. John .
NATURE IMMUNOLOGY, 2009, 10 (01) :29-37
[6]
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].
Curran, Michael A. ;
Montalvo, Welby ;
Yagita, Hideo ;
Allison, James P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280
[7]
A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9 [J].
de Weyer, Philipp S. van ;
Muehlfeit, Michael ;
Klose, Christoph ;
Bonventre, Joseph V. ;
Walz, Gerd ;
Kuehn, E. Wolfgang .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (02) :571-576
[8]
Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer [J].
Duraiswamy, Jaikumar ;
Freeman, Gordon J. ;
Coukos, George .
CANCER RESEARCH, 2013, 73 (23) :6900-6912
[9]
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T- cells to Be Suppressed In Vivo [J].
Durham, Nicholas M. ;
Nirschl, Christopher J. ;
Jackson, Christopher M. ;
Elias, Jimmy ;
Kochel, Christina M. ;
Anders, Robert A. ;
Drake, Charles G. .
PLOS ONE, 2014, 9 (11)
[10]
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients [J].
Fourcade, Julien ;
Sun, Zhaojun ;
Benallaoua, Mourad ;
Guillaume, Philippe ;
Luescher, Immanuel F. ;
Sander, Cindy ;
Kirkwood, John M. ;
Kuchroo, Vijay ;
Zarour, Hassane M. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (10) :2175-2186